11/13
07:46 am
bcab
BioAtla, Inc. (NASDAQ: BCAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Medium
Report
BioAtla, Inc. (NASDAQ: BCAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
11/8
04:12 pm
bcab
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
High
Report
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
11/7
04:18 pm
bcab
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]
Low
Report
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]
11/7
04:01 pm
bcab
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Medium
Report
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
10/31
08:00 am
bcab
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
Medium
Report
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
10/8
06:17 am
bcab
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy [Seeking Alpha]
Medium
Report
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy [Seeking Alpha]
10/7
11:38 am
bcab
BioAtla: Numerous Catalysts Coming In Q4 [Seeking Alpha]
Medium
Report
BioAtla: Numerous Catalysts Coming In Q4 [Seeking Alpha]
10/4
09:05 am
bcab
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Medium
Report
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
10/1
08:00 am
bcab
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
Medium
Report
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
9/23
03:55 pm
bcab
BioAtla out-licenses BA3362 to Context Therapeutics [Seeking Alpha]
Low
Report
BioAtla out-licenses BA3362 to Context Therapeutics [Seeking Alpha]
9/23
07:30 am
bcab
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Medium
Report
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
9/16
10:09 am
bcab
BioAtla, Inc. (NASDAQ: BCAB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
Medium
Report
BioAtla, Inc. (NASDAQ: BCAB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
9/16
08:00 am
bcab
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Soc
Medium
Report
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Soc
9/9
08:00 am
bcab
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
Medium
Report
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
9/4
09:59 am
bcab
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report 2024-2030, with Coverage of Akeso, Alphamab Oncology, BioAtla, BioNTech, Sino Biological and Xencor [Yahoo! Finance]
Neutral
Report
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report 2024-2030, with Coverage of Akeso, Alphamab Oncology, BioAtla, BioNTech, Sino Biological and Xencor [Yahoo! Finance]
9/4
09:19 am
bcab
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky [Yahoo! Finance]
Low
Report
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky [Yahoo! Finance]
8/28
08:00 am
bcab
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference